Erik Iverson
Impact in
-
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Blood Pressure and Hypertension Studies
-
- Diabetes Treatment and Management
- Hormonal Regulation and Hypertension
Papers in
-
- Influenza Virus Research Studies 3
-
- Heart Failure Treatment and Management 2
- Co-authors
- Susan Anderson (2 shared papers)Robert S. McKelvie (1 shared paper)Michel Komajda (1 shared paper)C Staiger (1 shared paper)Barry M. Massie (1 shared paper)Mark Donovan (1 shared paper)Agata Ptaszynska (1 shared paper)John J.V. McMurray (1 shared paper)
- Journals
- Clinical Infectious Diseases (1 paper)Clinical & Experimental Immunology (1 paper)Sexually Transmitted Infections (1 paper)The Lancet (1 paper)ACS Synthetic Biology (1 paper)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Erik Iverson
8 papers receiving 1.8k citations
Erik Iverson's Hit Papers
Peers
Comparison fields: 5 of 90
- Cardiology and Cardiovascular Medicine 1.2k
- Endocrinology, Diabetes and Metabolism 212
- Pharmacology 96
- Complementary and alternative medicine 46
- Epidemiology 135
Countries citing papers authored by Erik Iverson
This map shows the geographic impact of Erik Iverson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Iverson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Iverson more than expected).
Fields of papers citing papers by Erik Iverson
This network shows the impact of papers produced by Erik Iverson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Iverson. The network helps show where Erik Iverson may publish in the future.
Co-authors
The 25 scholars most cited alongside Erik Iverson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction Hit paper breakdown → | 2008 | 1381 |
| 2 | 2008 | 158 | |
| 3 | 2007 | 113 | |
| 4 | 2010 | 83 | |
| 5 | 2019 | 55 | |
| 6 | 2011 | 44 | |
| 7 | 2012 | 20 | |
| 8 | 2011 | 15 |
About Erik Iverson
Erik Iverson is a scholar working on Epidemiology, Cardiology and Cardiovascular Medicine, Molecular Biology, Pharmacology and Genetics, having authored 8 papers that have together received 1.9k indexed citations. Recurring topics across this work include Influenza Virus Research Studies (3 papers), Heart Failure Treatment and Management (2 papers), Biosensors and Analytical Detection (1 paper), Reproductive tract infections research (1 paper), Inflammatory mediators and NSAID effects (1 paper), Advanced biosensing and bioanalysis techniques (1 paper), Diabetes and associated disorders (1 paper) and CRISPR and Genetic Engineering (1 paper). The work is most often cited by research in Cardiology and Cardiovascular Medicine (1.2k citations), Endocrinology, Diabetes and Metabolism (212 citations), Pharmacology (96 citations), Complementary and alternative medicine (46 citations) and Epidemiology (135 citations). Erik Iverson has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Susan Anderson, Robert S. McKelvie, Michel Komajda, C Staiger, Barry M. Massie, Mark Donovan, Agata Ptaszynska, John J.V. McMurray, Michael R. Zile and Peter E. Carson. Their work appears in journals such as Clinical Infectious Diseases, Clinical & Experimental Immunology, Sexually Transmitted Infections, The Lancet and ACS Synthetic Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.